Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Public ClinicalTrials.gov record NCT00072852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a taxane, and capecitabine. Patients will receive Irinotecan capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.
Study identification
- NCT ID
- NCT00072852
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 134 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2003 (Type not available)
- Primary completion
- May 2007 (Actual)
- Completion
- May 2007 (Actual)
- Last update posted
- Oct 16, 2008
2003 – 2007
United States locations
- U.S. sites
- 57
- U.S. states
- 20
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36608 | — |
| Pfizer Investigational Site | Anchorage | Alaska | 99508 | — |
| Pfizer Investigational Site | Lewistown | Idaho | 83501 | — |
| Pfizer Investigational Site | Alton | Illinois | 62002 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46227 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66210 | — |
| Pfizer Investigational Site | Chalmette | Louisiana | 70043 | — |
| Pfizer Investigational Site | Covington | Louisiana | 70433 | — |
| Pfizer Investigational Site | Mandeville | Louisiana | 70448 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70002 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70006 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70115 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02115 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02130 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48201 | — |
| Pfizer Investigational Site | Southaven | Mississippi | 38671 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64111 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63136 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63141 | — |
| Pfizer Investigational Site | Washington | Missouri | 63090 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08901-2601 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08903 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | Stony Brook | New York | 11794 | — |
| Pfizer Investigational Site | Kettering | Ohio | 45409 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73120 | — |
| Pfizer Investigational Site | Greenville | South Carolina | 29615 | — |
| Pfizer Investigational Site | Covington | Tennessee | 38019 | — |
| Pfizer Investigational Site | Franklin | Tennessee | 37067 | — |
| Pfizer Investigational Site | Gallatin | Tennessee | 37066 | — |
| Pfizer Investigational Site | Hermitage | Tennessee | 37076 | — |
| Pfizer Investigational Site | Lebanon | Tennessee | 37087 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38120 | — |
| Pfizer Investigational Site | Murfreesboro | Tennessee | 37130 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37207 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37211 | — |
| Pfizer Investigational Site | Dallas | Texas | 75204 | — |
| Pfizer Investigational Site | Dallas | Texas | 75230-2510 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Fort Worth | Texas | 76104 | — |
| Pfizer Investigational Site | Plano | Texas | 75075-7787 | — |
| Pfizer Investigational Site | Tyler | Texas | 75702 | — |
| Pfizer Investigational Site | Federal Way | Washington | 98003 | — |
| Pfizer Investigational Site | Lakewood | Washington | 98499 | — |
| Pfizer Investigational Site | Seattle | Washington | 98104-2499 | — |
| Pfizer Investigational Site | Seattle | Washington | 98104 | — |
| Pfizer Investigational Site | Seattle | Washington | 98109-1023 | — |
| Pfizer Investigational Site | Seattle | Washington | 98122 | — |
| Pfizer Investigational Site | Seattle | Washington | 98195 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98405 | — |
| Pfizer Investigational Site | Vancouver | Washington | 98684 | — |
| Pfizer Investigational Site | Yakima | Washington | 98902 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00072852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2008 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00072852 live on ClinicalTrials.gov.